Main Menu Jump to Page


如果您持有PMTI的普通股,希望获取更多信息,请联系陈冠邦或者Phillip Kim律师。您可拨打对方付费电话866-767-3653,或邮件;或。咨询和诉讼代理均免费。



罗森律师事务所正在调查 Palomar Medical Technologies,的董事,在将公司出售给 Cynosure, Inc.过程中,是否违反了信托责任和某些州法。



Rosen Law Firm Announces Investigation of Palomar Medical Technologies, Inc. in Connection with its Sale to Cynosure, Inc. – PMTI

New York, N.Y., March 18, 2013:  The Rosen Law Firm, P.A. is investigating the Board of Directors of Palomar Medical Technologies, Inc. (“Palomar” or the “Company”) (NASDAQ GS: PMTI) for possible breaches of fiduciary duty and other violations of state law in connection with its sale of the Company to Cynosure, Inc. (“Cynosure”) (NASDAQ GS: CYNO).

If you would like to join the action please email or call Phillip Kim or Kevin Chan, toll-free, at 866-767-3653; or email at or  There is no cost or obligation to you.

Under the terms of the transaction, shareholders will receive $13.65 for each share of Palomar stock they own – $6.825 per share in cash and $6.825 per share in Cynosure common stock.  The investigation relates to whether the price of $13.65 per share in cash and Cynosure stock is fair to public shareholders and whether PMTI’s Board breached its fiduciary duties in connection with the transaction.

If you own Palomar common stock and wish to obtain additional information, you may contact Phillip Kim or Kevin Chan of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at or  

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising.  Prior results do not guarantee a similar outcome.